P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Luciano J. Costa,Parameswaran Hari,Jesus G. Berdeja,Valerio De Stefano,Francesca Gay,B. Hooper,M. Bartlett,Anja Haltner,Emily Rosta,Shaji Kumar,Thomas Martin,Maria-Victoria Mateos,Philippe Moreau,Saad Z. Usmani,Yunsi Olyslager,Jordan M. Schecter,Tito Roccia,A. Garrett,Sam Lee,Tonia Nesheiwat,Lida Bubuteishvili Pacaud,Changwei Zhou,Imtiaz A. Samjoo,Yi Lin,Joris Diels,Satish Valluri,Katja Weisel +26 more
TL;DR: Evaluating multiple indirect comparisons, cilta-cel demonstrated a significantly superior advantage over PCT, highlighting its effectiveness as a therapy in patients with triple-class exposed RRMM.
Journal ArticleDOI
Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results
Hang Quach,Gurdeep Parmar,Enrique M. Ocio,H. Miles Prince,Albert Oriol,Nobuhiro Tsukada,Kazutaka Sunami,Pierre Bories,Sumit Madan,Dorothée Semiond,Disa Yu,Sandrine Macé,Florence Suzan,Philippe Moreau +13 more
TL;DR: In this article , the authors evaluated the safety and efficacy of SC Isa in combination with pomalidomide and dexamethasone (Pd) for patients with relapsed/refractory multiple myeloma (RRMM).
Journal ArticleDOI
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Philippe Moreau,Thierry Facon,Saad Usmani,Nizar J. Bahlis,Noopur Raje,Torben Plesner,Robert Z. Orlowski,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Michael O'Dwyer,Aurore Perrot,Christopher P. Venner,Katja Weisel,Mourad Tiab,Margaret Macro,Laurent Frenzel,Xavier Leleu,Huiling Pei,Maria Krevvata,Robin Carson,Fredrik Borgsten,Shaji Kumar +24 more
TL;DR: The MAIA study as discussed by the authors evaluated D-Rd versus Rd alone in transplant-ineligible pts with NDMM and found that D-rd significantly improved progression-free survival (PFS) and overall survival versus Rd.
Journal ArticleDOI
Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults
Y. Le Bris,Thierry Guillaume,Anne-Lise Ménard,Marina Illiaquer,Jerome Martin,Stéphanie Malard,Alix Duquesne,Pierre Peterlin,Camille Debord,Nelly Robillard,Marion Eveillard,Soraya Wuilleme,Jacques Delaunay,Mohamad Mohty,Alice Garnier,Philippe Moreau,Marie-Christine Béné,Patrice Chevallier +17 more
TL;DR: In conclusion, expansion of T or B lymphocytes after UCB allo-HSCT in adults is not a rare event, and although occurring relatively late after transplant, this feature is predictive of a better outcome for the patients.
Journal ArticleDOI
Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study
Jean-Baptiste Alberge,Françoise Kraeber-Bodéré,Bastien Jamet,Cyrille Touzeau,Hélène Caillon,Soraya Wuilleme,Marie C. Béné,Tobias Kampfenkel,Pieter Sonneveld,Mark van Duin,Hervé Avet-Loiseau,Jill Corre,Florence Magrangeas,Thomas Carlier,Caroline Bodet-Milin,Michel Chérel,Philippe Moreau,Stephane Minvielle,Clément Bailly +18 more
TL;DR: The study confirmed and extended the association between imaging biomarkers and transcriptomic programs in MM and confirmed the combined prognostic value of PMD and a high-risk IFM15 signature may help define MM patients with a very high risk of progression.